One-time OCU410 gene therapy enters Phase 3 as Ocugen targets geographic atrophy treatment burden
Ocugen starts Phase 3 testing of one-time OCU410 gene therapy after a 31% reduction in geographic atrophy lesion growth in Phase 2.
Pharma & Biotech
Pharma & Biotech
Ocugen doses first patient in Phase 3 OCU410 gene therapy trial for geographic atrophy
Ocugen has begun the 237-patient Phase 3 ArMaDa3 trial of OCU410, a one-time gene therapy for geographic atrophy after Phase 2 treatment reduced lesion growth by 31% at 12 months.
Pharma & Biotech
FDA grants RMAT designation to OCU410 after Phase 2 geographic atrophy results
OCU410 receives FDA RMAT designation after Phase 2 data showed 31% slower geographic atrophy lesion growth with one gene therapy dose.
Pharma & Biotech
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Pharma & Biotech
Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.